Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study
Giulia Mallucci, Roberto Bergamaschi(Fondazione Istituto Neurologico Nazionale Casimiro Mondino), Angelo Ghezzi, Vittorio Mantero(Aziende Socio Sanitarie Territoriali di Lecco), P. Perini(University of Padua), Antonio Bertolotto(Neuroscience Institute), Roberto Balgera, Valentina Torri Clerici, Cristina Montomoli(University of Pavia), Gianfranco Costantini(University of Turin), Sara La Gioia(Ospedale Papa Giovanni XXIII), Marco Rovaris(San Raffaele University of Rome), Paola Cavalla, Silvia Miante(University of Padua), Stefania Rossi, Rosella Cavarretta(Don Carlo Gnocchi Foundation), Valentina D’Ambrosio(Istituti di Ricovero e Cura a Carattere Scientifico), Manuela Matta(Ospedale San Luigi Gonzaga), Pietro Annovazzi(Vita-Salute San Raffaele University), M. R. Rottoli(Ospedale Papa Giovanni XXIII), Mauro Zaffaroni(Associazione Italiana Sclerosi Multipla)
Cited by 35
Related Papers
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study
|The Lancet|2001|1.1k
Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN)
|The Lancet|2002|552
Evidence of early cortical atrophy in MS
|Neurology|2003|485